ImmuneOnco Announced Appointment of Dr. Xiaodong Gan as Senior Vice President for Clinical trials
On April 1, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") announced the appointment of Gan, Xiaodong as the senior vice president , mainly responsible for clinical trial affairs in the United States.
Dr. Gan, Xiaodong, graduated from the School of Pharmacy of Shanghai Medical University (now Fudan University), holds a bachelor's degree, master's degree and doctorate degree in pharmacy, and has more than 25 years of preclinical and clinical research experience in academia and biopharmaceutical industry.
Since 2004, Dr. Gan Xiaodong has successively employed by renowned pharmaceutical companies such as Merck, Bristol-Myers Squibb (BMS), Eli Lilly and Janssen worked on the clinical research and development, specializing in the development of metabolic diseases and oncology drugs. He has accumulated expensive practical experience in clinical research design, program formulation and implementation of clinical trials from Phase I to Phase III. He participated in the research and development of innovative drugs, covering both small molecule and macromolecular biological drugs. With experience in early stage drug development and clinical research at Merck, Bristol-Myers Squibb, Eli Lilly and Johnson & Johnson, he played an important role in the development of multiple clinical research strategies and led the implementation of global clinical research programs for the development of multiple drug products.
From October 2018 to March 2022, Dr. Gan, Xiaodong served as the VP of Italian NMS Pharmaceutical Group as the global head of clinical research and development. He comprehensively led the formulation and execution of global regulatory and clinical development strategies and approved to enter the international multi-center clinical research and development.
Dr. Tian, Wenzhi, founder, chairman and CEO of ImmuneOnco, said:
"I am very happy and sincerely welcome Dr. Xiaodong Gan to join the ImmuneOnco team. I fully believe that he will help our company to promote the development of innovative drugs rapidly with his extensive experience in clinical trial management of anti-tumor drugs, and accelerate the realization of our great vision, "developing first-class new drugs for the benefit of tumors patients'.
"We will work with all colleagues to build the company a world-renowned biopharmaceutical company and develop first-class of new anti-cancer drugs for cancer patients all around the world."